Cite this: Anti-TNF-α Agents in the Treatment of Immune-mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls - Medscape - Nov 01, 2010.

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with Crohn's disease. The resulting paper, "HLA DQA1*05 and risk of anti-TNF ...

Because of this, TNF inhibitors are often a first choice in a biologic. Five anti-TNF agents are approved for use in RA, each with different properties and mechanisms, but all of which block or ...

TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

The following is a summary of "Treatment Sequencing in Inflammatory Bowel Disease: Towards Clinical Precision Medicine," published in the March 2025 issue of Best Practice & Research Clinical ...

In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform ...

In the setting of early rheumatoid arthritis, when anti-TNF agents are used without corticosteroids or other immunosuppressives, their adverse effects are markedly attenuated compared with their ...

Furthermore, clinical and experimental studies show that the efficacy of the three currently licensed anti-TNF agents (infliximab, etanercept and adalimumab) may vary and depend on the type of ...